Deucravacitinib 1609392-27-9 Synthesis Process | Mass Production Quality Control and Supply Chain Solutions of Three Core Deuterated Intermediates

Meta Description: Focus on the industrial synthesis route of deuterated lexicotinib (Deucravacitinib), and explain in detail the quality control difficulties and mass production process of key intermediates; Covers deuterated methylamine hydrochloride 7436-22-8, 4,6-dichloro-N-(methyl-d3)-3-pyridazinecarboxamide 1609393-89-6, 4,6-dihydroxypyridazin-3-carboxylic acid monosodium salt 1442437-21-9-9-9-9, provide high-purity customized raw materials and compliance supply chain services for pharmaceutical companies CDMO and new drug declarations.

1. industry foreword

deuterium can be used as a differential TYK2 selective inhibitor (Deucravacitinib), which solves the problem of off-target toxicity of traditional JAK inhibitors by virtue of its unique deuterated methyl structure, and is the core target drug for the development of new drugs for autoimmune diseases. Compared with the popularity at the clinical application level, the barriers to the industrial synthesis of the drug are extremely high, and the core bottleneck is not the refining of the final API, but the purity and abundance control of the deuterated isotope block and the impurity control of the pyridine mother nuclear intermediate.

At present, a number of pharmaceutical companies around the world layout of deuterium can be used to improve the generics and improved new drugs, the core competition focus on low-cost, high-purity, stable isotope standards of the intermediate supply chain. In this paper, from the four dimensions of synthetic process logic, core intermediate role, key quality control parameters, mass production pain point solutions, dismantling the core points of industrial production of deuterium lexitinib API, for research and development, production, procurement personnel to provide accurate technical reference.

Process Parameters of 2. Deuterium and Lexitinib Core Products

3. Deuterium Celectinib Industrial Synthesis Core Logic

the mainstream industrial synthesis route of the industry adopts the four-step core process of parent nuclear construction-chlorinated modification-deuterated amidation-closed-loop refining, abandoning the inefficient synthesis path of the laboratory and adapting to large-scale mass production. The quality and yield of the whole process are completely determined by the three exclusive intermediates, and no alternative raw materials can be replaced:

first, 4,6-dihydroxypyridazine -3-carboxylic acid monosodium salt (1442437-21-9) is used as the starting parent material to build the pyridazine heterocyclic skeleton of the drug core. Dichloro-substituted intermediate was obtained through precise chlorination reaction, and then specific amide condensation was carried out with deuterated methylamine hydrochloride (7436-22-8), and patent-protected D3 deuterated methyl group was introduced to generate key advanced intermediate 4,6-dichloro-N-(methyl-d3)-3-pyridazinecarboxamide (1609393-89-6); Finally, high-purity deuterium recitinib API was obtained by ring-closing, deprotection and refined crystallization.

4. three core intermediates process value and quality control pain points detailed.

4.1 4,6-dihydroxypyridazine -3-carboxylic acid monosodium salt CAS:1442437-21-9 | parent core cornerstone raw material

this intermediate is the only starting building block for the deuterocolicetinib pyridazine heterocycle and belongs to the source core of the synthetic process. Compared with ordinary carboxylic acid raw materials, the sodium salt form has better water solubility and more stable reaction activity, and can greatly reduce the generation of by-products of chlorination reaction.

Process pain points and solutions: In industrial production, ordinary homemade mother nuclear raw materials are prone to isomeric impurities, resulting in total end-product impurities exceeding the standard. Our raw materials are purified by multi-stage recrystallization, HPLC purity is stable ≥ 98.5, heavy metals and ignition residues are strictly controlled, genetic impurities are eliminated from the source, and the production standards of drug declaration level are perfectly adapted.

4.2 Deuterated Methylamine Hydrochloride METHYL-D3-AMINE HYDROCHLORIDE CAS:7436-22-8 | Patented Structural Core Block

as the core isotope function block of the whole route, the raw material is the root cause of the long-acting and low-toxic properties of the deuterium, and is also the core of the drug patent barrier. Its function is to accurately introduce three deuterium atoms into drug molecules, replace ordinary methyl hydrogen atoms, and delay the metabolic rate of drugs in vivo.

Process pain points and solutions: low-cost products on the market generally have insufficient deuterium abundance, hydrogen isotope doping problems, will produce non-deuterium impurities, directly lead to drug declaration failure. Our product D3 isotope abundance stability ≥ 99atom%, no D1/D2 doping, batch stability is extremely strong, can meet the long-term commercial mass production and overseas high-end drug regulatory audit requirements.

4.3 4,6-dichloro-N-(methyl-d3)-3-pyridazinecarboxamide CAS:1609393-89-6 | Advanced Key Intermediates

the intermediate is the core product of the middle section of the synthesis route, has been completely integrated with the parent nucleus and deuterated methyl patent structure, only 3-4 steps from the final API refining reaction, is the core raw material for CDMO enterprises to shorten the research and development cycle, reduce cost efficiency.

Process pain points and solutions: The independent synthesis of this intermediate requires high-risk chlorination, water-free condensation reaction, harsh reaction conditions, low yield, high safety risk. Our company can directly provide pre-purified finished products with single impurity ≤ 0.1%, without secondary processing by customers, and can be directly put into subsequent closed-loop reaction, thus greatly shortening the production cycle and reducing the cost of three wastes treatment.

Comparison Table of Core Process Parameters of 5. Intermediates

6. FAQ section

q1: What is the core process card point for the synthesis of deuterium and lexitinib?

A: The core card point is not the final product refinement, but the precise introduction and abundance control of deuterated groups and the impurity control of pyridazine mother nucleus. The isotope purity of deuterated methylamine hydrochloride and the single impurity control of advanced intermediates are the key to determine whether the drug can pass the drug regulatory declaration.

Q2: Why can’t deuterated methylamine hydrochloride 7436-22-8 be replaced by ordinary methylamine?

A: Ordinary methylamine has no deuterium isotope structure, the synthetic product does not have the long-term and low-toxic properties of deuterium and may produce a large number of structurally similar impurities, which cannot meet the pharmacopoeia standards, and there is a serious risk of patent infringement, which cannot be used for new drug research and development and mass production.

Q3: What are the advantages of purchasing advanced intermediates 1609393-89-6 over independent synthesis?

A: It can avoid high-risk and low-yield process steps such as chlorination and waterless condensation, shorten the R & D and production cycle by more than 30%, reduce the cost and safety risk of three wastes treatment, and at the same time ensure the stability and control of impurities in the final product, so as to meet the needs of rapid declaration and rapid mass production.

Q4: Can the three intermediates provide a full set of information at the declaration level?

A: Support. Our company can provide each batch of COA quality inspection report, NMR, MS mass spectrometry, HPLC spectrum and impurity analysis report, which are fully compatible with IND and ANDA global new drug declaration specifications.

Q5: What is the mass production and supply capacity of deuterium lexicotinib intermediate?

A: Support g-class sample research and development, 100g-class pilot test, kg to ton-class commercial mass production, its own deuterated synthesis workshop and purification production line, can be long-term stable for the global CRO, CDMO, pharmaceutical enterprises to provide one-stop supply of raw materials.

Core advantages of 7. enterprise supply chain (B2B transformation orientation)

1. Full process chain matching: exclusive matching of deuterium can be used to synthesize the whole process of core raw materials, from the mother core starting materials, deuterium generation blocks to advanced intermediates, final API one-stop supply, to solve the customer multi-supplier procurement pain points.

2. Isotope process barriers: independent master of the core process of deuterium synthesis, to eliminate the problem of isotope abundance attenuation, batch consistency far beyond the industry average.

3. Compliance quality control: follow ICH Q7 API quality management practices, the whole process can be traced to meet the European and American, domestic drug regulatory audit standards.

4. Customized process services: according to the customer’s production process optimization of raw material indicators, to provide impurities customization, process improvement technical support.

5. Global compliance logistics: dangerous goods compliance packaging, support global shipping, air transport, the whole temperature control traceability, to ensure the quality of raw materials transportation stability.

8. CTA Call to Action

if you need deuterium lexitinib API(1609392-27-9) and three core intermediate sample testing, batch quotation and docking of process technology solutions, please feel free to consult and obtain exclusive technical white paper and full set of application materials.